Trial
NCT03846193
FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Gyroscope Therapeutics Limited
Collaborators
Novartis Pharmaceuticals
Condition
Dry Age-related Macular Degeneration
Intervention
GT005
Why stopped
The study was terminated due to the interim analysis demonstrating lack of treatment efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-28